Y90 Glass Microspheres

play icon
TheraSphere™ Y-90 Glass Microspheres
TheraSphere™ Dose Vial
TheraSphere™ Microspheres and Human Hair
TheraSphere™ Y-90 Glass Microspheres: How it’s Made
TheraSphere™ Dose Vial
TheraSphere™ Microspheres and Human Hair

TheraSphereTM Y90 Microspheres take advantage of a tumor’s hypervascularity and prioritise microsphere flow to the tumor. Because TheraSphereTM has high activity per sphere, fewer microspheres are needed to achieve the desired dose. The minimally embolic nature of TheraSphereTM preserves the patient’s vasculature and allows for safe and effective delivery of radiation without the risk of stasis and reflux and spares healthy tissue.


Product Description

TheraSphereTM allows for personalisation of treatment and greater flexibility by offering a multitude of standard and custom dose vial options to meet individual patient treatment goals. TheraSphereTM has demonstrated treatment success in a range of scenarios: curative or palliative, livers with single or multifocal tumors, portal vein thrombosis (PVT), and using segmental or lobar approaches1-6.

  1. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52(5):1741–9
  2. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79(1):163–71 
  3. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826–37 
  4. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60(1):192–201 
  5. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497–507
  6. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920–8


Mechanism of Action

A healthy liver receives most of its blood flow (75%) from the portal vein 1.  In HCC, tumor blood supply is almost exclusively from the hepatic artery (80-100%) 2. TheraSphereTM Y90 glass microspheres exploit tumor blood flow and are delivered to the tumor vasculature via catheterisation of the hepatic artery.

The glass microspheres penetrate the tumor arteriolar capillaries where they emit lethal beta radiation that is localised to the surrounding tumor tissue.3,4 The targeted distribution of microspheres provides high absorbed dose coverage to the tumor while sparing normal tissue.3,4,5,6

The high specific activity of TheraSphereTM Y90 glass microspheres means that fewer are administered to achieve the desired dose. As a result, glass microspheres are minimally embolic and do not occlude macrovessels.3 Since vessel  patency is maintained, subsequent arterial therapies are possible, if needed.3,7 

  1. Merkel C, Montagnese S, Amodio P. Functional Anatomy of Liver Circulation. Functional Molecular.
  2. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolisation of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolisation brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68(1):13–23.
  3. Salem R, Thurston KG. Radioembolisation with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251–78.
  4. Kulik M, Carr B, Mulcahy M, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47(1):71–81.
  5. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy off radioembolisation. Int J Radiat Oncol Biol Phys 2011;79(1):163–71.
  6. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolisation for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826–37.
  7. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolisation results in longer time-to-progression and reduced toxicity compared with chemoembolisation in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497–507.


Product Specifications and Sizes

TheraSphereTM consists of Y90 glass microspheres used in radiation treatment for patients with hepatic malignancies.

TheraSphereTM Y90 glass microspheres

  • Insoluble glass microspheres with a mean diameter of 15 to 35 μm
  • Y90 is an integral constituent of the glass

Yttrium-90 (Y-90)

  • Pure beta emitter
  • Average energy of 0.9367 MeV
  • Average tissue penetration range of 2.5 mm (max. 11 mm)

TheraSphere™ Order Form in PDF

Need a printed copy for your patient files? Please download the PDF on your computer, fill out the form and then submit directly to Customer Service or print out and fax your order.


Latest evidence with TheraSphere™

Major clinical data are building evidence of the benefits TheraSphereTM offers and are increasing understanding of how to optimise personalised treatment strategies in the treatment of primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and of mCRC (colorectal cancer that has metastasised to the liver).
Access the latest TheraSphereTM studies


Simplicit90Y™ provides a customised, easy-to-use dosimetry software developed for accelerating dosimetry planning and improving Y-90 SIRT workflow.